Dry powder inhaler

Primary Crystallization’s Influence on Fluticasone DPIs

Discover the impact of crystallization on mechanical properties & secondary processing of Fluticasone Propionate in dry powder inhaler formulations.

Understand how particle size impacts inhalation drug delivery and the role of dry powder inhalers (DPIs) in treating respiratory diseases.

Assess setups to combine Spraytec & Unidose™ for evaluating particle size distribution in dry powder inhalers.

Nanopharm investigate the pulmonary effect of Fluticasone and related compounds, addressing physiologic and pharmacokinetic challenges.

Nanopharm explores In Silico methods in the development of a Generic Tiotropium Dry Powder Inhaler (DPI). Learn how drug absorption is impacted.

Exploring the role of DPI (Dry powder inhaler) in drug development and the inhalation process and pharmacokinetics of fluticasone propionate.

Nanopharm investigate regional deposition and simulated inhaled pharmacokinetic profiles of generic dry powder inhalers.

Nanopharm explores annealing in micronized DPIs for drug development. Focus on molecular changes and SFE in Dry Powder Inhaler formulations.

Explore the dissolution kinetics of inhaled pharmaceuticals in dry powder inhalers (DPI) and pressurized metered dose inhalers (pMDI).

Explore automated classification of dry powder inhaler particles using Cluster Analysis and Morphologically Directed Raman Spectroscopy.